 |
|
Become an MS Research Champion NOW Brochure (.pdf) |
The complexity of MS necessitates a holistic approach when it comes to research – a comprehensive strategy that can propel knowledge, better treatments, health care policies, and new disease management therapies forward, faster.
We are a driving force of MS research and treatment to stop disease progression, restore function, and end MS forever.
The National MS Society supports and funds research activities spanning ALL research stages, including early discovery research, translational research that brings promising ideas forward into actual therapeutic solutions for testing, and clinical trials. Our unique approach drives the pursuit of all promising avenues that can impact those living with multiple sclerosis.
We drive progress through a comprehensive approach to research review and funding, including a variety of Society programs, and our Fast Forward initiative, focused on advancing the transition of promising new therapies to rapid commercial development and understanding mechanisms underlying the 
Intriguing Leads on the Horizon
Research News
Clinical Trials
Researchers Need You
How Far We’ve Come
For Researchers
Research We Fund
Recent Research News
MS Trial Alert: Investigators Recruiting for Study Comparing Exercise Programs to Improve Depression
Feb 08, 2012
Summary: Investigators at the University of Washington, Seattle, are recruiting 108 people with all types of MS or spinal cord injury nationwide for a study comparing the effects on depression of two telephone-coordinated exercise programs. The study, also called the inMotion study, is funded by the National Institutes on Disability and Rehabilitation Research.
MS Trial Alert: Pain Study Recruiting People with MS Nationwide
Feb 07, 2012
Summary: Investigators nationwide are recruiting 400 people with secondary-progressive MS or relapsing-remitting MS to compare the effectiveness of three doses of the oral drug AVP-923 (Nuedexta®, dextromethorphan hydrobromide and quinidine sulfate, Avanir Pharmaceuticals) or inactive placebo in reducing central neuropathic pain. The study is funded by Avanir Pharmaceuticals.
Research Teams Report on 18 Months of Progress from MS Societies’ Initial Studies on CCSVI and MS
Jan 27, 2012
Reports from 7 multi-disciplinary teams investigating CCSVI in MS indicate that they are making good progress toward providing essential data and critical analysis as these two-year projects move toward their completion. The studies were launched on July 1, 2010 with a more than $ 2.4 million commitment from the MS Society of Canada and the National MS Society (USA).